in

Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director

Carson City, Nevada–(Newsfile Corp. – April 27, 2022) – Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has appointed Mr. Dwayne Yaretz to the Board of Directors and as Chief Executive Officer. Mr. Yaretz replaces Mr. McEnulty, as CEO of the Company. Mr. McEnulty will continue to serve as a director of Cell MedX.

Mr. Yaretz’ experience spans many industries including the development of industrial and medical imaging devices. He has aided in the re-structure of numerous companies by identifying and recruiting key personnel, enhancing the management team, capitalization, and maximizing business and sales opportunities.

Mr. Yaretz has acted as a Director, President and CEO, Corporate Secretary and CFO for both private and public companies.

Mr. Yaretz commented, “I am excited to join the Cell MedX team, to prepare the Company to capitalize on its current Health Canada approvals for its eBalance® Systems, and in preparation of FDA 510K clearance to enter the US Market. It is my hope that Cell MedX will provide its rigorously tested microcurrent technology solution to millions of people who suffer from pain and would benefit from a safe, easy-to-use, non-invasive solution.”

Mr. McEnulty, Director and former CEO of the Company, stated, “We are very excited to welcome Mr. Yaretz to the Cell MedX team. His wealth of experience in the capital markets along with his manufacturing and medical devices background is a great asset to the Company.”

About Cell MedX Corp. (OTCQB: CMXC)

Cell MedX Corp. is a biotech company focused on the continued research and development of its eBalance® Technology and its eBalance® Home and eBalance® Pro Systems, which have received Health Canada Approval as Class II Medical Device Systems for pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities and lower extremities due to strain from exercise or normal household- or work-related activities, as well as for general relaxation. In addition, the Company will work towards the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. For more information about the Company and its technology please visit www.cellmedx.com

Source: https://finance.yahoo.com/news/cell-medx-corp-appoints-mr-130000562.html

Headlines

Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer

Headlines

Insulet Announces CEO Transition